Jaguar Health (JAGX) Company Report

On January 16, 2026, Jaguar Health, Inc. entered into multiple exchange agreements with Iliad Research and Trading, L.P. and Streeterville Capital, LLC.
The company issued pre-funded common stock purchase warrants in exchange for a $2,037,914.07 reduction in outstanding royalty interests.
Additionally, the company issued pre-funded common stock purchase warrants in exchange for the cancellation and retirement of 22 shares of Series L Preferred Stock from Iliad, 99.3822 shares of Series L Preferred Stock from Streeterville, 87.78 shares of Series M Preferred Stock from Iliad, and 69.44 shares of Series M Preferred Stock from Streeterville.
These transactions resulted in the issuance of pre-funded common stock purchase warrants to purchase a total of 11,776,281 shares of Common Stock. These warrants are exercisable at a nominal price of $0.001 per share and were issued under a registration exemption.

Jan 23, 2026, 9:15 PM

8-K

Jaguar Health Enters U.S. License Agreement with Future Pak for Crofelemer

JAGX

M&A

New Projects/Investments

Jaguar Health, Inc., through its wholly-owned subsidiary Napo Pharmaceuticals, Inc., entered into a U.S. license agreement with Future Pak, LLC and its affiliate Woodward Specialty LLC for Crofelemer (Mytesi® and Canalevia®-CA1) on January 12, 2026.
Under the terms of the agreement, Future Pak becomes the exclusive U.S. marketer for Mytesi® and Canalevia®-CA1.
Jaguar will receive an $18 million upfront payment, consisting of $16 million upon deal closing and $2 million upon completion of post-closing conditions.
Jaguar is eligible for up to an additional $20 million in milestone and other future payments, with milestone payments totaling up to $17 million based on cumulative Net Sales thresholds.
Jaguar will continue to manufacture Mytesi and Canalevia-CA1 for Future Pak, and this agreement provides Jaguar with meaningful non-dilutive capital, allowing it to focus on its rare-disease pipeline.

Jan 15, 2026, 10:05 PM

8-K

Jaguar Health Enters Licensing Agreement, Shifts Focus to Rare Disease R&D

JAGX

New Projects/Investments

Guidance Update

Jaguar Health (JAGX) has entered an exclusive license agreement with FuturePak for its Mytesi and Canalevia-CA1 products, valued at up to $38 million, including an $18 million upfront payment ($16 million already received).
This agreement enables Jaguar Health to transition into an R&D-focused biotech, concentrating on its pipeline, particularly rare disease programs such as microvillus inclusion disease (MVID) and short bowel syndrome (SBS).
The company aims for FDA filing for MVID by the end of 2026, potentially leading to breakthrough designation and a global regulatory filing, with the SBS market estimated at over $5 billion.
Jaguar Health will continue to manufacture crofelemer, which has become a profit center for the company.

Jan 15, 2026, 8:30 PM

Transcript

Jaguar Health Enters Licensing Agreement and Shifts Focus to R&D

JAGX

New Projects/Investments

Revenue Acceleration/Inflection

M&A

Jaguar Health (JAGX) entered an exclusive license agreement with FuturePak for Mytesi and Canalevia-CA1, valued at up to $38 million, including an upfront payment of $16 million received this week (published 2026-01-15).
This strategic shift allows Jaguar Health to become an R&D-focused biotech, concentrating on its rare disease pipeline, specifically microvillus inclusion disease (MVID) and short bowel syndrome (SBS).
The company aims for an FDA filing for MVID by the end of 2026, leveraging potential Breakthrough Designation and Prime Designation for accelerated approval pathways.
Jaguar Health will continue to manufacture crofelemer, which has become a profit center for the company.

Jan 15, 2026, 8:30 PM

Transcript

Jaguar Health Amends 8-K Filing, Details Securities Purchase Agreement

JAGX

Debt Issuance

Jaguar Health, Inc. filed an amended 8-K to correct the execution and closing dates of its securities purchase agreements to January 6, 2026.
The company issued $350,000 in aggregate principal amount of unsecured promissory notes to two accredited investors.
These notes bear an annual interest rate of 6% and will mature one month after issuance.
As an inducement, investors also received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share.
The proceeds from these agreements will be used for working capital and other general corporate purposes.

Jan 12, 2026, 11:04 AM

8-K

Jaguar Health Secures FDA Conditional Approval Renewal for Canalevia-CA1 and Pursues European Expansion

JAGX

Product Launch

New Projects/Investments

Jaguar Health announced the FDA approval of the renewal of the conditional approval for Canalevia-CA1, its plant-based drug for chemotherapy-induced diarrhea in dogs.
The company received a $250,000 grant to support the trial design for achieving full FDA approval for Canalevia-CA1 for chemotherapy-induced diarrhea in dogs.
Jaguar Health has filed with the European Medicines Agency (EMA) for advice to seek approval for all acute diarrhea in dogs, aiming for potential approval in 37 EU countries based on existing data.
The company is actively engaged in business development conversations to partner for expanding Canalevia-CA1's indication to all diarrhea in dogs in the U.S., addressing a market where approximately 15% of 90 million dogs present with acute diarrhea.

Dec 10, 2025, 8:25 PM

Transcript

Jaguar Health Secures FDA Conditional Approval Renewal for Canalivia and Pursues European Expansion

JAGX

New Projects/Investments

Product Launch

Jaguar Health (JAGX) announced the FDA renewal of conditional approval for Canalivia for chemotherapy-induced diarrhea in dogs on December 10, 2025, which led to a 20%-25% increase in its stock on that day.
The company recently received a $250,000 grant to support the trial design for full FDA approval of Canalivia for chemotherapy-induced diarrhea in dogs.
Jaguar Health has also filed with the European Medicines Agency (EMA) for advice on seeking approval for all acute diarrhea in dogs, potentially allowing for approval in 37 EU countries based on existing data.
The company anticipates 2026 and early 2026 to be a significant period of catalysts, driven by clinical data and regulatory clarity on both human and animal health fronts, including potential partnerships for the Canalivia program.

Dec 10, 2025, 8:25 PM

Transcript

Jaguar Health Provides Update on Canine Drug Approval and European Expansion Plans

JAGX

New Projects/Investments

Guidance Update

Jaguar Health (JAGX) announced the FDA approval of the renewal of the conditional approval for Canalivia for chemotherapy-induced diarrhea in dogs.
The company received a $250,000 grant to support the confirmatory trial required for full approval of Canalivia for this indication.
Following the announcement, Jaguar Health's stock experienced a 20%-25% increase.
Jaguar Health has filed with the EMA in Europe to seek advice on approval for all acute diarrhea in dogs and is engaging in business development conversations for U.S. partnerships to expand Canalivia's indications.
The company anticipates 2026 will be a significant year for catalysts driven by clinical data and regulatory progress.

Dec 10, 2025, 8:25 PM

Transcript

Jaguar Health Updates on Crofelemer Clinical Trials and New Ventures

JAGX

New Projects/Investments

Product Launch

Guidance Update

Jaguar Health reported that its Phase 3 OnTarget trial for crofelemer in cancer treatment-related diarrhea (CTD) did not meet its primary endpoint for all tumor types but showed significant results in a prespecified subgroup of adult breast cancer patients.
Initial proof-of-concept results presented in April 2025 indicated that crofelemer reduced Total Parenteral Nutrition (TPN) in patients with Microvillus Inclusion Disease (MVID) by up to 27% and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 12.5%.
The company formed Magdalena Biosciences, a joint venture with Filament Health and One Small Planet, to develop botanical pharmaceutical drug candidates for mental health illnesses, with Jaguar owning approximately 40%.
Canalevia-CA1, conditionally approved by the FDA in December 2021 for chemotherapy-induced diarrhea in dogs and launched in April 2022, is being pursued for expanded approval for general diarrhea in all dogs.

Dec 9, 2025, 11:00 PM

Presentation

Jaguar Health Stockholders Approve All Proposals at Special Meeting

JAGX

Proxy Vote Outcomes

Convertible Preferred Issuance

Jaguar Health, Inc. stockholders approved all three proposals at the Special Meeting held on December 8, 2025.
Key approvals included the issuance of Common Stock upon exchange and/or redemption of Series N Preferred Stock and the issuance of New PIPE Shares and a Pre-Funded PIPE Warrant.
The company reported initial positive results from an investigator-initiated trial demonstrating that crofelemer can potentially extend the lives of infants with intestinal failure due to MVID, showing a PS reduction of up to 37%.
Jaguar Health also met with the FDA on October 2, 2025, to discuss an expedited approval pathway for crofelemer for the treatment of MVID.